Related Experiment Videos
Complications and monitoring of OKT3 therapy
J R Thistlethwaite1, J K Stuart, J T Mayes
1Department of Surgery, University of Chicago Medical Center, IL 60637.
Abstract:
Complications of OKT3 therapy were studied in 122 treatment episodes in renal allograft recipients (83 for rejection treatment, 39 for immunosuppression induction). A febrile first-dose reaction to OKT3 was common; no severe pulmonary complications were encountered. Other toxicities of OKT3 therapy were observed later in the treatment course. Most severe were the occurrence of aseptic meningitis in four patients (3%), and seizures in eight (6%). Seizures occurred only when OKT3 was given to patients with nonfunctioning grafts due to acute tubular necrosis. Infections were the only significant late adverse sequelae of OKT3 therapy and occurred more frequently after multiple exposures to the drug (53%) than after a single exposure (22%). IgG antibodies to OKT3 developed after 45% of exposures to the drug in the 74 patients in whom appearance of anti-OKT3 antibodies was monitored. In two patients (3%), anti-OKT3 antibodies were detected before the end of the OKT3 treatment course, neutralizing the immunosuppressive property of the drug. In five patients (7%), strong anti-OKT3 antibody responses were present at the time of subsequent rejection, which precluded reuse of the drug. In 17 other cases, no or only a weak anti-OKT3 response was detectable at the time of rejection following initial OKT3 exposure. Retreatment with OKT3 was successful in reversing rejection in 15 cases (88%). No untoward sequelae were noted after reexposure to OKT3, except the high incidence of subsequent infections.
Insights
Muromonab-CD3 (OKT3) therapy in renal transplant patients can cause side effects like fever, aseptic meningitis, and seizures. Infections are a significant risk, especially after repeated OKT3 exposure.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- Muromonab-CD3 (OKT3) is an immunosuppressive monoclonal antibody used in renal transplantation.
- Its use is associated with potential complications and adverse events.
Purpose of the Study:
- To evaluate the safety and efficacy of OKT3 therapy in renal allograft recipients.
- To identify complications, adverse sequelae, and antibody development associated with OKT3 treatment.
Main Methods:
- Retrospective analysis of 122 OKT3 treatment episodes in renal allograft recipients.
- Monitoring for adverse events, including febrile reactions, meningitis, seizures, infections, and antibody formation.
Main Results:
- Common first-dose febrile reactions occurred; severe pulmonary complications were absent.
- Aseptic meningitis (3%) and seizures (6%) were observed, with seizures linked to nonfunctioning grafts.
- Infections were the most frequent late adverse event, occurring more often after multiple OKT3 exposures (53%) than single exposures (22%).
- IgG antibodies to OKT3 developed in 45% of monitored patients, sometimes neutralizing efficacy or precluding retreatment.
- Retreatment with OKT3 was successful in 88% of cases, with infections being a notable sequela.
Conclusions:
- OKT3 therapy is associated with manageable acute toxicities and significant risks of infection, particularly with repeated use.
- The development of anti-OKT3 antibodies can impact drug efficacy and retreatment options.
- Careful monitoring for infections and antibody formation is crucial during OKT3 therapy in renal transplant recipients.